TRANSFUSION SCIENCE


n Patients with warm autoagglutinins and/or a positive DAT.


n Determining Rh variants. n Testing when rare serological antisera is not available.


n Testing to resolve discrepant weak serology phenotypes.


Aim of the study


This study aims to investigate the use of Sickledex as a screening method to identify HbS-negative donors and to implement a molecular red cell extended genotyping test kit to allow NIBTS to retain an accurate genotyping record when extended RBC phenotyping is not possible, in keeping with guideline recommendations and to aid with appropriate selection of blood for transfusion purposes.


Materials and methods Sickledex


After assessment of a number of methodologies, the Sickledex (Streck, through Alpha Laboratories) method of haemoglobin S (HbS) screening was selected, due to its low cost and ease of use. When Sickledex reagent powder is combined with Sickledex solubility buffer and a blood sample is added, a patient’s blood sample that


Fig 2. When using the Sickledex screening test, a patient’s blood sample that contains HbS will form a cloudy, turbid suspension.


contains HbS will form a cloudy, turbid suspension (Fig 2). One hundred samples were tested for HbS using the sickle solubility test (which included random EDTA donor samples, random donor units, and EDTA samples


from known SCD patients. Six samples from known SCD patients were also included within these to verify positive results, which were then compared with capillary electrophoresis confirmation results.


PATHOLOGY HORIZONS 2024 18 - 20 April | Bath | England


Positive Negative


Discover The Future of Pathology


Scan Here To Register Now


WWW.PATHOLOGYINPRACTICE.COM APRIL 2024


43


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57